Drug Evaluation

*Author for correspondence: Tel.: +33 320 445 343;

E-mail Address: pauline.wils@chru-lille.fr

Inserm, CHU Lille, U1286 - INFINITE - Institute for Translational Research in Inflammation, University of Lille, F-59000 Lille, France

Department of Gastroenterology, Centre Hospitalier Régional Universitaire de Lille, University of Lille, 59000, France

Search for more papers by this author

Laurent Peyrin-Biroulet

University of Lorraine, CHRU-Nancy, Department of Gastroenterology, F-54000 Nancy, France

University of Lorraine, Inserm, NGERE, F-54000 Nancy, France

Search for more papers by this author

Published Online:15 Feb 2023https://doi.org/10.2217/imt-2022-0255

View article

Abstract

Sphingosine-1-phosphate (S1P) and its receptor (S1PR) are involved in the pathogenesis of multiple immune-mediated inflammatory disorders, including inflammatory bowel disease. The use of S1PR modulators represents a new therapeutic option for ulcerative colitis patients. Etrasimod is an oral selective S1PR1, S1PR4 and S1PR5 modulator that inhibits the trafficking of lymphocytes from the lymph nodes into the blood. Recently, etrasimod has demonstrated efficacy in the phase II OASIS study and its open-label extension for the treatment of ulcerative colitis patients. This article reviews the mechanism of action of etrasimod and summarizes the available clinical efficacy and safety data regarding etrasimod, which is a promising drug in the treatment of patients with moderate to severe ulcerative colitis.

Plain language summary

Etrasimod is a new and promising drug for ulcerative colitis patients. Ulcerative colitis is a chronic inflammatory bowel disease caused by the body's inability to control its immune system. This leads to immune cell recruitment in the lining of the colon, causing inflammation. Etrasimod helps to control the level of immune cells in the blood, which means that fewer immune cells reach the lining of the colon, reducing inflammation. Etrasimod is fast-acting and given once a day by mouth and has demonstrated promising efficacy and safety in the phase II OASIS study and its open-label extension for the treatment of ulcerative colitis patients. Therefore, etrasimod may expand treatment options for patients with moderate to severe ulcerative colitis.

Tweetable abstract

In this review, the authors summarize the mechanism of action of etrasimod and provide an update on the available clinical efficacy and safety data regarding etrasimod for the treatment of ulcerative colitis.

Keywords:

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

1. Hoivik ML, Moum B, Solberg IC et al. Health-related quality of life in patients with ulcerative colitis after a 10-year disease course: results from the IBSEN study. Inflamm. Bowel Dis. 18(8), 1540–1549 (2012).
MedlineGoogle Scholar
2. Chang JT. Pathophysiology of inflammatory bowel diseases. N. Engl. J. Med. 383(27), 2652–2664 (2020).
Medline CASGoogle Scholar
3. Amiot A, Peyrin-Biroulet L. Current, new and future biological agents on the horizon for the treatment of inflammatory bowel diseases. Therap. Adv. Gastroenterol. 8(2), 66–82 (2015).
MedlineGoogle Scholar
4. Danese S, Allez M, van Bodegraven AA et al. Unmet medical needs in ulcerative colitis: an expert group consensus. Dig. Dis. 37(4), 266–283 (2019).
MedlineGoogle Scholar
5. Ng SC, Shi HY, Hamidi N et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet 390(10114), 2769–2778 (2018).
MedlineGoogle Scholar
6. Fumery M, Singh S, Dulai PS, Gower-Rousseau C, Peyrin-Biroulet L, Sandborn WJ. Natural history of adult ulcerative colitis in population-based cohorts: a systematic review. Clin. Gastroenterol. Hepatol. 16(3), 343–356.e3 (2018).
MedlineGoogle Scholar
7. Solberg IC, Lygren I, Jahnsen J et al. Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN study). Scand. J. Gastroenterol. 44(4), 431–440 (2009).
MedlineGoogle Scholar
8. Singh S, George J, Boland BS, Vande Casteele N, Sandborn WJ. Primary non-response to tumor necrosis factor antagonists is associated with inferior response to second-line biologics in patients with inflammatory bowel diseases: a systematic review and meta-analysis. J. Crohns Colitis 12(6), 635–643 (2018).
MedlineGoogle Scholar
9. Buisson A, Serrero M, Orsat L et al. Comparative acceptability of therapeutic maintenance regimens in patients with inflammatory bowel disease: results from the nationwide ACCEPT2 study. Inflamm. Bowel Dis. izac119 (2022).
MedlineGoogle Scholar
10. Burisch J, Jess T, Martinato M, Lakatos PL. The burden of inflammatory bowel disease in Europe. J. Crohns Colitis 7(4), 322–337 (2013).
MedlineGoogle Scholar
11. Ma C, Lee JK, Mitra AR et al. Systematic review with meta-analysis: efficacy and safety of oral Janus kinase inhibitors for inflammatory bowel disease. Aliment. Pharmacol. Ther. 50(1), 5–23 (2019).
Medline CASGoogle Scholar
12. Pyne NJ, Pyne S. Sphingosine 1-phosphate receptor 1 signaling in mammalian cells. Molecules 22(3), 344 (2017).
MedlineGoogle Scholar
13. McGinley MP, Cohen JA. Sphingosine 1-phosphate receptor modulators in multiple sclerosis and other conditions. Lancet 398(10306), 1184–1194 (2021). • Describes the sphingosine-1-phosphate (S1P) pathway and its regulation.
Medline CASGoogle Scholar
14. Kappos L, Radue E-W, O'Connor P et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N. Engl. J. Med. 362(5), 387–401 (2010).
Medline CASGoogle Scholar
15. Sandborn WJ, Feagan BG, D'Haens G et al. Ozanimod as induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med. 385(14), 1280–1291 (2021). • Phase III clinical trial showing efficacy data of ozanimod for the treatment of ulcerative colitis (UC).
Medline CASGoogle Scholar
16. Buzard DJ, Kim SH, Lopez L et al. Discovery of APD334: design of a clinical stage functional antagonist of the sphingosine-1-phosphate-1 receptor. ACS Med. Chem. Lett. 5(12), 1313–1317 (2014).
Medline CASGoogle Scholar
17. Al-Shamma H, Lehmann-Bruinsma K, Carroll C et al. The selective sphingosine 1-phosphate receptor modulator etrasimod regulates lymphocyte trafficking and alleviates experimental colitis. J. Pharmacol. Exp. Ther. 369(3), 311–317 (2019). • Describes the mechanism of action of etrasimod with regard to modulating lymphocyte trafficking.
Medline CASGoogle Scholar
18. Argollo M, Furfaro F, Gilardi D et al. Modulation of sphingosine-1-phosphate in ulcerative colitis. Expert Opin. Biol. Ther. 20(4), 413–420 (2020).
Medline CASGoogle Scholar
19. Camm J, Hla T, Bakshi R, Brinkmann V. Cardiac and vascular effects of fingolimod: mechanistic basis and clinical implications. Am. Heart J. 168(5), 632–644 (2014).
Medline CASGoogle Scholar
20. Schwab SR, Pereira JP, Matloubian M, Xu Y, Huang Y, Cyster JG. Lymphocyte sequestration through S1P lyase inhibition and disruption of S1P gradients. Science 309(5741), 1735–1739 (2005).
Medline CASGoogle Scholar
21. Garris CS, Blaho VA, Hla T, Han MH. Sphingosine-1-phosphate receptor 1 signalling in T cells: trafficking and beyond. Immunology 142(3), 347–353 (2014).
Medline CASGoogle Scholar
22. Matloubian M, Lo CG, Cinamon G et al. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature 427(6972), 355–360 (2004).
Medline CASGoogle Scholar
23. Verstockt B, Vetrano S, Salas A et al. Sphingosine 1-phosphate modulation and immune cell trafficking in inflammatory bowel disease. Nat. Rev. Gastroenterol. Hepatol. 19(6), 351–366 (2022).
Medline CASGoogle Scholar
24. Schreiber S, Morgan M, Christopher R et al. Etrasimod (APD334), a potent, selective, oral S1P receptor modulator with preclinical autoimmune disease-modifying activity exhibits favorable PK/PD properties in healthy volunteers. Presented at: Advances in Inflammatory Bowel Diseases. Orlando, FL, USA, 8–10 December 2016.
Google Scholar
25. Peyrin-Biroulet L, Adams J, Turner S et al. Safety and immune modulatory properties of etrasimod (APD334), a next-generation oral, selective sphingosine 1-phosphate receptor (S1PR) modulator, in healthy volunteers. Presented at: 13th Congress of the European Crohn's and Colitis Organisation. Vienna, Austria, 14–17 February 2018.
Google Scholar
26. Sandborn WJ, Peyrin-Biroulet L, Zhang J et al. Efficacy and safety of etrasimod in a phase 2 randomized trial of patients with ulcerative colitis. Gastroenterology 158(3), 550–561 (2020). •• Phase II study that provides efficacy data of etrasimod for the treatment of patients with moderate to severe UC.
Medline CASGoogle Scholar
27. Vermeire S, Chiorean M, Panés J et al. Long-term safety and efficacy of etrasimod for ulcerative colitis: results from the open-label extension of the OASIS study. J. Crohns Colitis 15(6), 950–959 (2021).
MedlineGoogle Scholar
28. Oh DA, Lee CA, Tang Y et al. Steady-state trough concentrations and their relationship to selected demographic and clinical response measures in etrasimod-treated patients with moderately-to-severely active ulcerative colitis. World Congress of Gastroenterology, Istanbul, Turkey (2019).
Google Scholar
29. Gilardi D, Gabbiadini R, Allocca M et al. PK, PD, and interactions: the new scenario with JAK inhibitors and S1P receptor modulators, two classes of small molecule drugs, in IBD. Expert Rev. Gastroenterol. Hepatol. 14(9), 797–806 (2020).
Medline CASGoogle Scholar
30. Bristol Myers Squibb Pharma EEIG. Zeposia (ozanimod hydrochloride) capsules for oral use: US prescribing information (2021). (Accessed 3 August 2022). https://daily med.nlm.nih.gov
Google Scholar
31. Lee CA et al. Mass balance, metabolic disposition, and pharmacokinetics of [¹⁴C] etrasimod following oral administration to healthy male volunteers. American Association of Pharmaceutical Scientists (2019).
Google Scholar
32. Lee CA, Acevedo L, Oh DA et al. P396 pharmacokinetics and circulating total lymphocyte count pharmacodynamic response from single and multiple oral doses of etrasimod in Japanese and Caucasian healthy male subjects. J. Crohns Colitis 14(Suppl. 1), S36 8 (2020).
Google Scholar
33. Lee C, Ramaiya A, Tang Y et al. OP27 a phase 1 study evaluating the bioequivalence of the proposed commercial and clinical formulations of etrasimod 2mg and the effect of food on the pharmacokinetics of the proposed commercial formulation in healthy volunteers. J. Crohns Colitis 16(Suppl. 1), i029 (2022).
Google Scholar
34. Lee C. P291 pharmacokinetics, safety, and tolerability of etrasimod (APD334) in subjects with mild, moderate, or severe hepatic impairment: a single-dose, open-label, parallel-group study. J. Crohns Colitis 15(Suppl. 1), S321–S322 (2021).
Google Scholar
35. Taylor C, Tang Y, Villa-Caballero L, Liu K, Randle A, Grundy JS. P208 effect of coadministration of etrasimod on the pharmacokinetics and pharmacodynamics of a monophasic oral contraceptive. Gut 71(Suppl. 1), A142 (2022).
Google Scholar
36. Taylor C, Chiorean M, Vermeire S et al. P209 etrasimod improves quality of life in adults with moderate-to-severe ulcerative colitis. Gut 71(Suppl. 1), A143 (2022).
Google Scholar
37. Pfizer. Pfizer presents ELEVATE pivotal findings demonstrating etrasimod’s potentially best-in-class profile in ulcerative colitis. www.pfizer.com/news/press-release/press-release-detail/pfizer-presents-elevate-pivotal-findings-demonstrating
Google Scholar
38. US National Library of Medicine. Etrasimod versus placebo as induction therapy in moderately to severely active ulcerative colitis (ELEVATE UC 12). https://clinicaltrials.gov/ct2/show/NCT03996369
Google Scholar
39. US National Library of Medicine. Etrasimod versus placebo for the treatment of moderately to severely active ulcerative colitis (ELEVATE UC 52). https://clinicaltrials.gov/ct2/show/NCT03945188
Google Scholar
40. Sandborn WJ, Vermeire S, Peyrin-Biroulet L et al. 968A: etrasimod 2mg once daily as treatment for moderately to severely active ulcerative colitis: results from the phase 3 ELEVATE UC 52 and ELEVATE UC 12 trials. Gastroenterology 162(Suppl. 7), S1395 (2022). •• First results of phase III clinical trial of etrasimod 2 mg for inducing and maintaining clinical remission in patients with moderate to severe UC.
Google Scholar

Vol. 15, No. 5

Metrics

Downloaded 1,070 times

History

Received 8 October 2022

Accepted 24 January 2023

Published online 15 February 2023

Published in print April 2023

Information

Keywords

Disclosure

In addition to the peer review process, with the authors' consent, the manufacturer of the product discussed in this article was given the opportunity to review the manuscript for factual accuracy. Changes were made by the authors at their discretion and based on scientific or editorial merit only. The authors maintained full control over the manuscript, including content, wording and conclusions.

Financial & competing interests disclosure

L Peyrin-Biroulet receives personal fees from Galapagos, AbbVie, Janssen, Genentech, Alimentiv, Ferring Pharmaceuticals, Tillotts Pharma, Celltrion, Takeda, Pfizer, InDex Pharmaceuticals, Sandoz, Celgene, Biogen, Samsung Bioepis, Inotrem, Allergan, MSD, Roche, Arena Pharmaceuticals, Gilead, Amgen, Bristol Myers Squibb, CSL Vifor, Norgine, Mylan, Lilly, Fresenius Kabi, OSE Immunotherapeutics, Enthera, Theravance Biopharma, Pandion Therapeutics, Gossamer Bio, Viatris, Thermo Fisher Scientific, Ono Pharmaceutical, Mopac, Cytoki Pharma, Morphic Therapeutic, Prometheus Biosciences and Applied Molecular Transport. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Data availability statement

No new data were generated or analyzed in support of this research.

PDF download

Etrasimod for the treatment of ulcerative colitis

Abstract

Plain language summary

Tweetable abstract

References